Bio-Techne (TECH) reported $1.2B in revenue for fiscal 2025, +5.2% year on year. That ranks #1654 by revenue among 2853 SEC filers and #153 in Healthcare. Net income was $73.4M, a net margin of 6.0%. Revenue has grown 10.4% a year on average since 2016 ($499M then). The fiscal 2025 balance sheet shows $2.5B in total assets, $173M in cash and $260M in long-term debt.
Key figures
| Key figures | FY2025 | YoY | Source |
|---|---|---|---|
| RevenueRevenueFromContractWithCustomerExcludingAssessedTax | $1.2B | +5.2% | FY20252025-06-30 |
| Gross profitGrossProfit | $790M | +2.7% | FY20252025-06-30 |
| Operating incomeOperatingIncomeLoss | $102M | −50.5% | FY20252025-06-30 |
| Net incomeNetIncomeLoss | $73.4M | −56.3% | FY20252025-06-30 |
| Operating cash flowNetCashProvidedByUsedInOperatingActivities | $288M | −3.8% | FY20252025-06-30 |
| Capital expenditurePaymentsToAcquirePropertyPlantAndEquipment | $31.0M | −50.7% | FY20252025-06-30 |
| Total assetsAssets | $2.5B | −5.5% | FY20252025-12-31 |
| Shareholders' equityStockholdersEquity | $2.0B | −3.2% | FY20252025-12-31 |
| CashCashAndCashEquivalentsAtCarryingValue | $173M | −2.6% | FY20252025-12-31 |
| Long-term debtLongTermDebtAndCapitalLeaseObligations | $260M | −13.3% | FY20252025-12-31 |
Revenue is total net sales for the fiscal year, taken from each company's own annual filing.
Reported since the last full year
Three-month figures this company has filed since FY2025. A quarter is not comparable with a full year, and these figures are used nowhere else on the site: not in any ranking, not in comparisons, not in the download.
| Quarter | Revenue | Net income | Source |
|---|---|---|---|
| Q1 20262026-03-31 | $311M | $51.0M | Open → |
Only periods that end on a calendar quarter appear here. A company whose fiscal year ends in June files on a different calendar, so it has no row.
Where this sits in its sector
Each bar is the spread of the whole sector: the box covers the middle half of companies, the line inside it the median, and the triangle this company. The axis is clipped at the 5th and 95th percentile so a single outlier does not flatten it.
| Where this sits in its sector | FY2025 | Position in sector |
|---|---|---|
| Net marginRank 81 of 161 companies compared | 6.0% | |
| Operating marginRank 93 of 160 companies compared | 8.4% | |
| R&D as share of revenueRank 50 of 102 companies compared | 8.2% | |
| Cash as share of revenueRank 70 of 160 companies compared | 14.2% |
All four are ratios derived from two reported lines, not single filing items. Peer group: companies in the same sector with revenue of $1bn or more; loss-making companies are included.
Profile
- Legal name
- Bio-Techne Corp
- Ticker
- TECH
- Exchange
- Nasdaq
- SIC classification
- Biological Products, (No Diagnostic Substances) (2836)
- Fiscal year end
- 06-30
- CIK
- 0000842023
Filings
- 10-KAug 24, 2026Open filing →
- 10-QMay 6, 2026Open filing →
- 10-QFeb 4, 2026Open filing →
Similar in size, same sector
| Company | Revenue | Net income |
|---|---|---|
| Lakefront BiotherapeuticsLKFT | $1.3B | $363M |
| Indivior PharmaceuticalsINDV | $1.2B | $210M |
| Nasus PharmaNSRX | $1.2B | −$5.9M |
| Bio-TechneTECH | $1.2B | $73.4M |
| Trulieve CannabisTRLV | $1.2B | −$116M |
| Sotera HealthSHC | $1.2B | $77.9M |
| NovavaxNVAX | $1.1B | $440M |
Cite this page
Ready-made references for the figures on this page, as published on September 25, 2026.
Wikipedia
{{cite web |title=Bio-Techne — Key figures |url=https://companiesranked.com/en/company/bio-techne |website=CompaniesRanked |date=2026-09-25 |language=en}}APA 7
CompaniesRanked. (September 25, 2026). Bio-Techne — Key figures. CompaniesRanked. https://companiesranked.com/en/company/bio-techneBibTeX
@misc{companiesranked-en-company-bio-techne-2026,
author = {{CompaniesRanked}},
title = {{Bio-Techne — Key figures}},
year = {2026},
howpublished = {\url{https://companiesranked.com/en/company/bio-techne}},
note = {Compiled from SEC EDGAR XBRL filings; data as of 2026-09-25},
urldate = {2026-09-25}
}The filing itself
The numbers above are read from this document: 10-K · 0001104659-26-100322 · August 24, 2026
{{cite web |title=Bio-Techne — Key figures — 10-K (0001104659-26-100322) |url=https://www.sec.gov/Archives/edgar/data/842023/000110465926100322/tech-20260630x10k.htm |website=SEC EDGAR |publisher=U.S. Securities and Exchange Commission |date=2026-08-24}}The figures are rebuilt with every data refresh, so the reference carries the publication date. Add your own access date if your style requires one.